Oxytetracycline (LA-200, Biomycin)

Oxytetracycline stands as one of the most widely utilized broad-spectrum antibiotics in food animal production, representing a cornerstone of veterinary therapeutics for over six decades. This tetracycline-class antibiotic demonstrates remarkable efficacy against a diverse array of gram-positive and gram-negative bacteria, as well as certain mycoplasmas, rickettsiae, and chlamydiae that commonly affect livestock species. The medication has earned its reputation as an indispensable tool in managing bacterial infections across cattle, swine, sheep, goats, and poultry operations worldwide.

The mechanism of action underlying oxytetracycline's antimicrobial activity involves binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis essential for bacterial growth and reproduction. This bacteriostatic action prevents susceptible organisms from multiplying, allowing the animal's immune system to effectively eliminate the infection. The drug exhibits excellent tissue penetration and achieves therapeutic concentrations in respiratory tissues, making it particularly valuable for treating pneumonia and other respiratory conditions prevalent in confined livestock operations.

Oxytetracycline is commercially available in multiple formulations designed to accommodate various administration routes and treatment scenarios. The long-acting injectable formulation, marketed as LA-200 and similar products, provides sustained therapeutic blood levels for up to 72 hours following a single injection, reducing handling stress and labor requirements. Standard injectable preparations, oral powders for water medication, feed additives, and topical ophthalmic formulations provide veterinarians and producers with flexible treatment options suited to individual animal treatment or mass medication programs.

From a regulatory standpoint, oxytetracycline maintains FDA approval for use in multiple food animal species, though recent antimicrobial stewardship initiatives have resulted in increased veterinary oversight requirements. Injectable formulations now require a veterinary prescription, reflecting the broader industry commitment to judicious antibiotic use and resistance prevention. Producers must maintain accurate treatment records and strictly observe established withdrawal periods to ensure food safety and regulatory compliance.

Oxytetracycline's labeled indications span a comprehensive range of bacterial infections affecting food-producing animals, with particular prominence in respiratory disease complexes that challenge livestock production systems. In cattle, the medication serves as a primary treatment option for bovine respiratory disease (BRD), addressing infections caused by Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. The drug's ability to achieve effective concentrations in lung tissue makes it especially valuable during high-risk periods such as receiving and backgrounding phases when respiratory challenges peak.

Beyond respiratory applications, oxytetracycline demonstrates proven efficacy against infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis, a condition causing significant economic losses through reduced weight gains and potential permanent vision impairment. The medication effectively treats interdigital necrobacillosis (foot rot) caused by Fusobacterium necrophorum, addressing this painful condition that severely impacts animal mobility and productivity. Wooden tongue (actinobacillosis), leptospirosis, and bacterial enteritis represent additional labeled indications where oxytetracycline provides reliable therapeutic outcomes.

Swine producers rely on oxytetracycline for managing bacterial pneumonia, atrophic rhinitis, leptospirosis, and enteric infections including bacterial scours in young pigs. The medication's effectiveness against Actinobacillus pleuropneumoniae and other respiratory pathogens makes it valuable in swine respiratory disease complexes. Treatment of erysipelas infections, though penicillin remains the preferred agent, may incorporate oxytetracycline as an alternative option.

In sheep and goat production, oxytetracycline addresses pneumonia, foot rot, bacterial enteritis, and vibrionic abortion with established efficacy. Poultry operations utilize the medication for controlling chronic respiratory disease (CRD), infectious synovitis, and fowl cholera, typically administered through water or feed medication systems that facilitate flock-wide treatment.

Extra-label applications, conducted under valid veterinarian-client-patient relationships, extend oxytetracycline's utility to conditions such as anaplasmosis treatment and prevention, tick-borne diseases, and certain reproductive tract infections. These applications require careful attention to extended withdrawal periods as determined by FARAD guidelines, ensuring meat and milk safety when animals eventually enter the food supply.

Proper dosing of oxytetracycline requires careful attention to species-specific requirements, formulation characteristics, and treatment objectives to achieve optimal therapeutic outcomes while minimizing adverse effects and resistance development. For cattle receiving long-acting injectable oxytetracycline (LA-200, Biomycin 200), the standard labeled dose is 9 mg per pound of body weight (20 mg/kg) administered intramuscularly or subcutaneously. This dosage typically translates to 1 mL per 10 pounds of body weight for the 200 mg/mL concentration products. A single injection provides therapeutic blood levels for approximately 72 hours, though severe infections may warrant repeat treatment following label guidelines.

Standard oxytetracycline injectable formulations (100 mg/mL) require administration at 3-5 mg per pound of body weight (6.6-11 mg/kg) daily or every other day, depending on infection severity and product-specific labeling. Intravenous administration, where labeled, demands slow injection to prevent cardiovascular effects, with the total dose typically divided if exceeding certain volumes. Subcutaneous injection sites should be limited to 10 mL per location in cattle to minimize tissue damage and injection site lesions that could affect carcass quality.

Swine dosing follows similar weight-based calculations, with injectable oxytetracycline administered at 3-5 mg per pound intramuscularly. Injection volumes should not exceed 5 mL per site in mature swine, with smaller volumes appropriate for younger animals. Water medication programs typically provide 10-50 mg per bird daily for poultry, adjusted based on water consumption patterns and ambient temperature affecting intake.

Administration technique significantly impacts treatment success and animal welfare outcomes. Intramuscular injections should utilize clean, appropriately sized needles (16-18 gauge for cattle) changed frequently to maintain sterility and injection comfort. Injection sites in the neck region anterior to the shoulder minimize potential carcass trim losses while providing adequate muscle mass for product absorption. Proper restraint ensures accurate dosing and reduces injection-site complications from animal movement.

Withdrawal times represent critically important compliance requirements for oxytetracycline use in food animals. Long-acting injectable formulations carry a 28-day slaughter withdrawal for cattle, reflecting the extended tissue persistence designed to provide prolonged therapeutic activity. Standard injectable preparations typically require 18-22 day meat withdrawals depending on specific product labeling. Milk from treated dairy cattle must be discarded for 96 hours following the last treatment with most injectable formulations. Swine meat withdrawal periods range from 22-28 days based on product formulation. Producers must consult specific product labels and maintain accurate treatment records documenting animal identification, treatment dates, products used, and withdrawal completion dates.

For extra-label drug use, extended withdrawal periods calculated through FARAD consultation ensure food safety when oxytetracycline is used outside labeled parameters. These situations require direct veterinary involvement and documentation of the extended withdrawal period communicated to the producer.

Oxytetracycline generally demonstrates favorable tolerability across food animal species when administered according to label directions, though several adverse effects warrant recognition and monitoring. The most commonly observed side effects relate to local tissue reactions at injection sites, particularly following intramuscular administration of concentrated long-acting formulations. These reactions may include transient swelling, firmness, and discoloration that typically resolve over several weeks but can result in permanent tissue scarring affecting carcass value if injection site guidelines are not followed.

Gastrointestinal disturbances represent another recognized adverse effect category, particularly relevant when oxytetracycline is administered orally. Alterations in normal gut microflora may produce loose stools, reduced feed intake, or secondary overgrowth of resistant organisms. Young animals appear more susceptible to these effects, and concurrent probiotic administration may help maintain digestive function during treatment periods. Oral formulations should be administered with attention to proper mixing and concentration to avoid gastrointestinal irritation from overly concentrated solutions.

Injection site reactions in cattle can be substantial with long-acting formulations, potentially creating lesions exceeding 100 square centimeters in some animals. These reactions reflect the inherent tissue irritation of the propylene glycol and polyvinylpyrrolidone vehicles used to achieve sustained release characteristics. Strict adherence to neck injection sites and volume limitations per site minimizes the economic impact of these predictable tissue effects. Cold product temperatures may exacerbate injection site reactions, and allowing refrigerated products to reach room temperature before administration can reduce this concern.

Serious adverse effects, while uncommon with properly administered oxytetracycline, include potential cardiovascular effects from rapid intravenous administration, nephrotoxicity with prolonged high-dose therapy, and hepatotoxicity in severely compromised animals. Tetracyclines can deposit in developing bone and teeth, causing permanent discoloration in young animals, though this effect holds primarily cosmetic rather than functional significance in food animals. Photosensitization reactions may occur, particularly in animals with white or lightly pigmented skin exposed to intense sunlight during treatment.

Species-specific toxicity considerations include heightened sensitivity in young calves, where kidney function immaturity may prolong drug elimination and increase toxicity risk. Horses represent a notable exception where oxytetracycline and other tetracyclines carry significant risks of fatal colitis and should not be administered to this species. Rapid intravenous administration in any species can cause cardiovascular collapse, and this route should only be utilized when specifically labeled and with appropriate slow injection techniques.

Several important contraindications govern oxytetracycline use in food animal production, requiring careful patient assessment before treatment initiation. Animals with documented hypersensitivity to tetracycline-class antibiotics should not receive oxytetracycline, as cross-reactivity among tetracycline compounds is expected. While true allergic reactions are relatively uncommon in food animals, previous adverse responses to any tetracycline product warrant alternative antibiotic selection.

Renal impairment represents a significant contraindication for oxytetracycline therapy, as the drug undergoes substantial renal elimination and can accumulate to toxic levels in animals with compromised kidney function. Animals presenting with dehydration require careful fluid status correction before tetracycline administration, as the combination of reduced renal blood flow and tetracycline nephrotoxicity potential creates unacceptable risk. Severely debilitated animals with suspected hepatic dysfunction similarly warrant cautious evaluation, given the potential for tetracycline hepatotoxicity in compromised individuals.

Age-related restrictions apply to oxytetracycline use in very young animals, where developing skeletal and dental tissues may incorporate the drug with permanent effects. While this consideration carries less significance in food animals than in companion species, awareness of potential effects on bone development in neonatal animals receiving high or prolonged doses remains appropriate. The drug should not be used in animals intended for breeding if dental appearance is commercially relevant.

Species restrictions critically exclude horses and other equids from oxytetracycline treatment, as this class is highly susceptible to fatal antimicrobial-associated colitis following tetracycline administration. The disruption of normal hindgut fermentation can produce rapidly fatal outcomes, and no clinical situation justifies tetracycline use in horses. Concurrent use of oxytetracycline with nephrotoxic drugs, including aminoglycoside antibiotics and certain non-steroidal anti-inflammatory drugs, is contraindicated due to additive kidney damage potential.

Oxytetracycline participates in several clinically significant drug interactions that veterinarians and producers must recognize to avoid therapeutic failures and adverse outcomes. Perhaps most critically in livestock production settings, tetracyclines demonstrate antagonistic interactions with bactericidal antibiotics including penicillins and cephalosporins. The bacteriostatic mechanism of tetracyclines, which inhibits bacterial protein synthesis, can interfere with the bactericidal activity of beta-lactam antibiotics that require actively dividing bacteria for optimal effect. When possible, these drug classes should not be combined, or if combination therapy is deemed necessary, the bactericidal agent should be administered first.

Divalent and trivalent cation interactions significantly impact oxytetracycline bioavailability when the drug is administered orally. Calcium, magnesium, aluminum, iron, and zinc form insoluble chelation complexes with tetracyclines, dramatically reducing gastrointestinal absorption. This interaction carries particular significance for water and feed medication programs where mineral content of the water source or feed can substantially diminish therapeutic efficacy. Calcium-rich supplements, mineral blocks, and high-mineral feeds should not be provided concurrently with oral oxytetracycline therapy. A minimum two-hour separation between tetracycline administration and mineral supplementation helps avoid this interaction.

Ionophore antibiotics, widely used as coccidiostats and growth promotants in cattle and poultry, require careful consideration when combined with oxytetracycline therapy. While direct pharmacokinetic interactions are not established, the combined use of multiple antimicrobials in food animals raises both resistance concerns and potential for additive toxicity in stressed animals. Monensin, lasalocid, and similar ionophores should be used with attention to overall antimicrobial load and potential effects on drug metabolism.

Warfarin and other anticoagulant medications demonstrate enhanced activity when combined with tetracycline antibiotics, likely through displacement from plasma protein binding sites and effects on vitamin K-producing gut bacteria. This interaction holds minimal relevance in typical food animal production but may be significant in valuable breeding animals receiving anticoagulant therapy. Methoxyflurane anesthesia, though now rarely used, creates enhanced nephrotoxicity risk when combined with tetracyclines. Antacid products containing aluminum, magnesium, or calcium hydroxide substantially reduce tetracycline absorption and should be avoided in treated animals.

Human safety precautions during oxytetracycline handling warrant careful attention, as the drug can cause sensitization reactions in handlers with repeated exposure. Personnel administering injectable oxytetracycline should wear appropriate gloves to prevent skin contact, which may cause local irritation and potential sensitization. Accidental self-injection represents a significant concern with any veterinary injectable, and proper restraint techniques along with awareness of needle placement help prevent these incidents. Should accidental injection occur, immediate medical attention is advisable, with the product label and safety data sheet available for the treating physician.

Food safety and residue avoidance represent paramount concerns in oxytetracycline use within food animal production systems. Strict adherence to labeled withdrawal periods ensures that meat, milk, and eggs from treated animals do not contain violative antibiotic residues when they enter the food supply. Producers must maintain detailed treatment records including animal identification, treatment dates, products used, dosages administered, and calculated withdrawal completion dates. Animals must not be sent to slaughter before withdrawal completion, and milk from treated dairy cattle must be discarded for the specified period. Residue violations carry significant regulatory and economic consequences, including potential criminal penalties for repeated violations.

Antimicrobial resistance stewardship demands judicious oxytetracycline use focused on appropriate indications with confirmed or strongly suspected susceptible bacterial involvement. The broad-spectrum nature of tetracyclines creates selection pressure across multiple bacterial populations, potentially promoting resistance development. Culture and sensitivity testing, where practical, helps confirm appropriate antibiotic selection. Completing prescribed treatment courses helps eliminate infections fully and reduces the bacterial populations from which resistant strains emerge. Underdosing, which may occur through inaccurate weight estimation or improper product dilution, creates subtherapeutic drug concentrations that promote resistance while failing to resolve infections.

Environmental considerations include appropriate disposal of unused product, empty containers, and used needles. Oxytetracycline containers should never be repurposed for water or feed storage. Needle disposal in approved sharps containers prevents human injury and environmental contamination. The drug demonstrates environmental persistence with potential effects on soil microorganisms, though agricultural use typically results in manageable environmental exposure levels.

Proper treatment record maintenance supports both regulatory compliance and herd health management. Records should document the veterinarian prescribing the medication, treated animals (individual or group identification), diagnosis or indication, product used including lot number, dosage and route, treatment dates, and withdrawal period. These records must be retained for a minimum of two years in most jurisdictions and made available for regulatory inspection upon request.

Proper storage of oxytetracycline products maintains drug stability and ensures full potency throughout the product shelf life. Injectable formulations should be stored at controlled room temperature between 59°F and 86°F (15°C to 30°C), protected from light exposure that can degrade the active ingredient. Refrigeration is generally not required and may actually cause precipitation or crystallization in some formulations. Products stored below recommended temperatures should be allowed to return to room temperature and inspected for particulate matter or discoloration before use. Any product showing visible precipitation, unusual color, or cloudiness should be discarded.

Multi-dose vial handling requires attention to aseptic technique to prevent contamination that could compromise product sterility and animal safety. Clean needles should be used for each entry into multi-dose containers, and rubber stoppers should be wiped with alcohol before needle insertion. Once punctured, multi-dose vials should be used within the timeframe specified on the product label, typically 28 days for most injectable oxytetracycline formulations. Dating the vial upon first puncture helps track this period. Vials should be stored upright after opening to maintain stopper integrity.

Product disposal follows regulatory requirements for pharmaceutical waste, with unused product and empty containers disposed of according to local and federal guidelines. Empty oxytetracycline containers should not be reused for any purpose and should be rendered non-retrievable before disposal. Needles and syringes require disposal in approved sharps containers to prevent human injury and environmental contamination. Many veterinary practices and agricultural supply stores offer sharps disposal services. Large quantities of expired or unused product may require disposal through approved pharmaceutical waste handlers, and consultation with local environmental authorities can clarify specific requirements.

Species and breed-specific considerations significantly influence oxytetracycline dosing strategies and monitoring requirements across the diversity of food animal production systems. Cattle breeds vary in their response to intramuscular injections, with heavily muscled beef breeds potentially showing different drug distribution patterns compared to dairy types. Bos indicus breeds (Brahman and Brahman-influenced cattle) may demonstrate altered pharmacokinetics due to differences in body composition and fat distribution, though oxytetracycline dosing recommendations generally remain consistent across beef and dairy breeds. The emphasis on neck injection sites applies universally to protect carcass value regardless of breed or production type.

Dairy cattle present unique considerations due to milk withdrawal requirements that impact operation economics. Treatment decisions in lactating dairy cows must account for the economic loss from discarded milk during the withdrawal period, which may influence product selection or treatment timing. Dry cow therapy with oxytetracycline follows established protocols, with attention to appropriate product selection and withdrawal period completion before calving. Beef cattle lack milk withdrawal concerns but require particular attention to pre-slaughter withdrawal periods and injection site management.

Small ruminant species (sheep and goats) demonstrate important pharmacokinetic differences from cattle that affect dosing recommendations. Goats generally metabolize drugs more rapidly than sheep, potentially requiring higher doses or more frequent administration to maintain therapeutic concentrations. However, specific labeled doses should be followed when available, with extra-label dosing conducted only under veterinary guidance with appropriate withdrawal period adjustments. Sheep breeds vary considerably in body composition, and accurate weight estimation supports proper dosing.

Swine production systems typically employ oxytetracycline in younger animals for enteric and respiratory disease management. The rapid growth rates of modern swine genetics require frequent weight reassessment to ensure appropriate dosing as animals gain. Individual animal treatment in swine facilities presents handling challenges that may favor water or feed medication approaches for group therapy. Breeding stock and show pigs require attention to injection site healing and any permanent tissue effects.

Within the tetracycline class, several related compounds offer alternative options for specific clinical situations or when oxytetracycline resistance is suspected. Chlortetracycline, available primarily as a feed additive, provides similar spectrum coverage with different pharmacokinetic properties suited to continuous low-level administration. Tetracycline itself remains available in certain formulations, though oxytetracycline has largely superseded it due to superior tissue penetration and longer duration of action. Doxycycline, while less commonly used in food animals due to extended withdrawal requirements, offers enhanced lipophilicity and potentially better penetration of certain tissues.

Macrolide antibiotics represent the primary alternative antibiotic class for respiratory disease treatment when tetracycline resistance or treatment failure occurs. Tulathromycin (Draxxin), tilmicosin (Micotil), and gamithromycin (Zactran) provide excellent respiratory tissue concentrations with convenient single-dose or extended-duration therapy. These agents offer different resistance profiles and may be effective against tetracycline-resistant respiratory pathogens. Florfenicol (Nuflor) provides broad-spectrum activity including against some tetracycline-resistant strains and serves as a valuable alternative for bovine respiratory disease.

Combination products incorporating oxytetracycline with other therapeutic agents exist for specific applications. Oxytetracycline-neomycin combinations target enteric infections with complementary spectrum coverage. Some products combine tetracyclines with anti-inflammatory agents or vitamins for supportive care during infectious disease treatment. Selection among available options should consider confirmed or suspected pathogen susceptibility, withdrawal period requirements, ease of administration, and cost-effectiveness for the specific production situation.